Dilutive/Non- Dilutive10 Apr 2019 11:59
As you know there has been a lot of discussion here lately about our funding, in fact it has been going on for four years!!!, lol.
Whilst we are pretty quiet here now, I posted this around 10.00 Monday on the way out. It was something i have been thinking about for some time, was waiting for a "quiet""time to discuss it, some chance. Will just repost it and welcome any views, variations and thoughts (not insults!!!) It is the model i believe that would be perfect for us going forward and more important realistic IMHO.................................
CHELSEA7
Posts: 35,358
Premium Chat Member
Opinion: Strong Buy
Price: 5.20
RE: April 25thMon 10:41Morning.
Soulac, thanks for that, another link from Pro-active...........................
https://www.proactiveinvestors.co.uk/companies/news/214474/scancell-in-vanguard-of-immuno-oncology-advances-with-two-technologies-that-show-early-promise-214474.html
Good news today, although expected. Seems to me with Patents nearly all in place, the timing could be right to see a partner take Moditope through clinical development where necessary and trials, whilst Scancell remain as developers of novel vaccines, building deeper into existing pipelines or new platforms.
IF Moditope proves as good as we expect it would make good business sense to take the pipeline through clinical trials, sharing profits with Scancell on commercialisation, whilst Scancell add to the existing pipelines.
Sure sounds a better option than some being put forward, again I think Scancell don"t need us to suggest that alternative, lol.
Have a good day all.
Reply | Recommend 6 |
Again, all thoughts welcome, but sensible ones.